Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma

State-of-the-science

Camillo Porta, Roberto Sabbatini, Giuseppe Procopio, Chiara Paglino, Enzo Galligioni, Cinzia Ortega

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Although over 70% of patients with metastatic renal cell carcinoma (RCC) respond to initial therapy with tyrosine kinase inhibitors (disease control rate 70-80%), approximately 20-30% of patients do not respond to first-line therapy and progress within ≤3 months. Understanding the mechanisms of resistance to targeted therapies is vital in the development of prospectively defined sequences and because the choice of first-line therapy determines that of second and subsequent line therapy, identification of the optimal first-line therapy is a priority for clinicians treating patients with metastatic RCC. By preselecting those patients most likely to respond to antivascular endothelial growth factor therapy, clinicians can begin to optimize therapeutic strategies. This review focuses on primary antivascular endothelial growth factor-refractory patients and the move towards individualizing treatment for RCC. The authors include a review of the growing number of studies, as yet retrospective, which provide important information on the group of primary refractory patients with advanced RCC for whom the prognosis is not good. First, the percentage of primary refractory patients (26%) is in agreement with disease control rate - the sum of objective responses and disease stabilization, observed in registration studies for a range of tyrosine kinase inhibitors. Second, the prognosis for these patients is poor as they do not respond to first-line nor to second-line therapy, and changing the mechanism of action (with inhibition of mTOR pathway) does not appear to produce additional benefits. Third and most importantly, the results of these studies demonstrate the need to better characterize the mechanism of primary resistance to current therapeutic agents with the ultimate aim of developing a therapeutic strategy for this important subgroup of patients.

Original languageEnglish
Pages (from-to)1571-1577
Number of pages7
JournalExpert Review of Anticancer Therapy
Volume12
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Endothelial Growth Factors

Keywords

  • molecular mechanism
  • primary
  • refractory
  • renal cell carcinoma
  • resistance
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma : State-of-the-science. / Porta, Camillo; Sabbatini, Roberto; Procopio, Giuseppe; Paglino, Chiara; Galligioni, Enzo; Ortega, Cinzia.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 12, 12.2012, p. 1571-1577.

Research output: Contribution to journalArticle

@article{0cf43565498645a08a98d46f8df816d3,
title = "Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: State-of-the-science",
abstract = "Although over 70{\%} of patients with metastatic renal cell carcinoma (RCC) respond to initial therapy with tyrosine kinase inhibitors (disease control rate 70-80{\%}), approximately 20-30{\%} of patients do not respond to first-line therapy and progress within ≤3 months. Understanding the mechanisms of resistance to targeted therapies is vital in the development of prospectively defined sequences and because the choice of first-line therapy determines that of second and subsequent line therapy, identification of the optimal first-line therapy is a priority for clinicians treating patients with metastatic RCC. By preselecting those patients most likely to respond to antivascular endothelial growth factor therapy, clinicians can begin to optimize therapeutic strategies. This review focuses on primary antivascular endothelial growth factor-refractory patients and the move towards individualizing treatment for RCC. The authors include a review of the growing number of studies, as yet retrospective, which provide important information on the group of primary refractory patients with advanced RCC for whom the prognosis is not good. First, the percentage of primary refractory patients (26{\%}) is in agreement with disease control rate - the sum of objective responses and disease stabilization, observed in registration studies for a range of tyrosine kinase inhibitors. Second, the prognosis for these patients is poor as they do not respond to first-line nor to second-line therapy, and changing the mechanism of action (with inhibition of mTOR pathway) does not appear to produce additional benefits. Third and most importantly, the results of these studies demonstrate the need to better characterize the mechanism of primary resistance to current therapeutic agents with the ultimate aim of developing a therapeutic strategy for this important subgroup of patients.",
keywords = "molecular mechanism, primary, refractory, renal cell carcinoma, resistance, tyrosine kinase inhibitor",
author = "Camillo Porta and Roberto Sabbatini and Giuseppe Procopio and Chiara Paglino and Enzo Galligioni and Cinzia Ortega",
year = "2012",
month = "12",
doi = "10.1586/era.12.81",
language = "English",
volume = "12",
pages = "1571--1577",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma

T2 - State-of-the-science

AU - Porta, Camillo

AU - Sabbatini, Roberto

AU - Procopio, Giuseppe

AU - Paglino, Chiara

AU - Galligioni, Enzo

AU - Ortega, Cinzia

PY - 2012/12

Y1 - 2012/12

N2 - Although over 70% of patients with metastatic renal cell carcinoma (RCC) respond to initial therapy with tyrosine kinase inhibitors (disease control rate 70-80%), approximately 20-30% of patients do not respond to first-line therapy and progress within ≤3 months. Understanding the mechanisms of resistance to targeted therapies is vital in the development of prospectively defined sequences and because the choice of first-line therapy determines that of second and subsequent line therapy, identification of the optimal first-line therapy is a priority for clinicians treating patients with metastatic RCC. By preselecting those patients most likely to respond to antivascular endothelial growth factor therapy, clinicians can begin to optimize therapeutic strategies. This review focuses on primary antivascular endothelial growth factor-refractory patients and the move towards individualizing treatment for RCC. The authors include a review of the growing number of studies, as yet retrospective, which provide important information on the group of primary refractory patients with advanced RCC for whom the prognosis is not good. First, the percentage of primary refractory patients (26%) is in agreement with disease control rate - the sum of objective responses and disease stabilization, observed in registration studies for a range of tyrosine kinase inhibitors. Second, the prognosis for these patients is poor as they do not respond to first-line nor to second-line therapy, and changing the mechanism of action (with inhibition of mTOR pathway) does not appear to produce additional benefits. Third and most importantly, the results of these studies demonstrate the need to better characterize the mechanism of primary resistance to current therapeutic agents with the ultimate aim of developing a therapeutic strategy for this important subgroup of patients.

AB - Although over 70% of patients with metastatic renal cell carcinoma (RCC) respond to initial therapy with tyrosine kinase inhibitors (disease control rate 70-80%), approximately 20-30% of patients do not respond to first-line therapy and progress within ≤3 months. Understanding the mechanisms of resistance to targeted therapies is vital in the development of prospectively defined sequences and because the choice of first-line therapy determines that of second and subsequent line therapy, identification of the optimal first-line therapy is a priority for clinicians treating patients with metastatic RCC. By preselecting those patients most likely to respond to antivascular endothelial growth factor therapy, clinicians can begin to optimize therapeutic strategies. This review focuses on primary antivascular endothelial growth factor-refractory patients and the move towards individualizing treatment for RCC. The authors include a review of the growing number of studies, as yet retrospective, which provide important information on the group of primary refractory patients with advanced RCC for whom the prognosis is not good. First, the percentage of primary refractory patients (26%) is in agreement with disease control rate - the sum of objective responses and disease stabilization, observed in registration studies for a range of tyrosine kinase inhibitors. Second, the prognosis for these patients is poor as they do not respond to first-line nor to second-line therapy, and changing the mechanism of action (with inhibition of mTOR pathway) does not appear to produce additional benefits. Third and most importantly, the results of these studies demonstrate the need to better characterize the mechanism of primary resistance to current therapeutic agents with the ultimate aim of developing a therapeutic strategy for this important subgroup of patients.

KW - molecular mechanism

KW - primary

KW - refractory

KW - renal cell carcinoma

KW - resistance

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84871514484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871514484&partnerID=8YFLogxK

U2 - 10.1586/era.12.81

DO - 10.1586/era.12.81

M3 - Article

VL - 12

SP - 1571

EP - 1577

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 12

ER -